A Multi-Analyte Assay for the Non-Invasive Detection of Bladder Cancer

Steven Goodison, Myron Chang, Yunfeng Dai, Virginia Urquidi, Charles J. Rosser

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Accurate urinary assays for bladder cancer (BCa) detection would benefit both patients and healthcare systems. Through genomic and proteomic profiling of urine components, we have previously identified a panel of biomarkers that can outperform current urine-based biomarkers for the non-invasive detection of BCa. Herein, we report the diagnostic utility of various multivariate combinations of these biomarkers. We performed a case-controlled validation study in which voided urines from 127 patients (64 tumor bearing subjects) were analyzed. The urinary concentrations of 14 biomarkers (IL-8, MMP-9, MMP-10, SDC1, CCL18, PAI-1, CD44, VEGF, ANG, CA9, A1AT, OPN, PTX3, and APOE) were assessed by enzyme-linked immunosorbent assay (ELISA). Diagnostic performance of each biomarker and multivariate models were compared using receiver operating characteristic curves and the chi-square test. An 8-biomarker model achieved the most accurate BCa diagnosis (sensitivity 92%, specificity 97%), but a combination of 3 of the 8 biomarkers (IL-8, VEGF, and APOE) was also highly accurate (sensitivity 90%, specificity 97%). For comparison, the commercial BTA-Trak ELISA test achieved a sensitivity of 79% and a specificity of 83%, and voided urine cytology detected only 33% of BCa cases in the same cohort. These datashow that a multivariate urine-based assay can markedly improve the accuracy of non-invasive BCa detection. Further validation studies are under way to investigate the clinical utility of this panel of biomarkers for BCa diagnosis and disease monitoring.

Original languageEnglish (US)
Article numbere47469
JournalPLoS One
Volume7
Issue number10
DOIs
StatePublished - Oct 19 2012
Externally publishedYes

Fingerprint

Biomarkers
Urinary Bladder Neoplasms
Assays
biomarkers
assays
urine
Urine
Immunosorbents
Validation Studies
interleukin-8
Matrix Metalloproteinases
Interleukin-8
Vascular Endothelial Growth Factor A
stromelysin 2
Bearings (structural)
Enzyme-Linked Immunosorbent Assay
Urinary Bladder Diseases
enzyme-linked immunosorbent assay
Cytology
Sensitivity and Specificity

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

A Multi-Analyte Assay for the Non-Invasive Detection of Bladder Cancer. / Goodison, Steven; Chang, Myron; Dai, Yunfeng; Urquidi, Virginia; Rosser, Charles J.

In: PLoS One, Vol. 7, No. 10, e47469, 19.10.2012.

Research output: Contribution to journalArticle

Goodison, Steven ; Chang, Myron ; Dai, Yunfeng ; Urquidi, Virginia ; Rosser, Charles J. / A Multi-Analyte Assay for the Non-Invasive Detection of Bladder Cancer. In: PLoS One. 2012 ; Vol. 7, No. 10.
@article{9366f71db7bf444f99aa8f8fe15dfc91,
title = "A Multi-Analyte Assay for the Non-Invasive Detection of Bladder Cancer",
abstract = "Accurate urinary assays for bladder cancer (BCa) detection would benefit both patients and healthcare systems. Through genomic and proteomic profiling of urine components, we have previously identified a panel of biomarkers that can outperform current urine-based biomarkers for the non-invasive detection of BCa. Herein, we report the diagnostic utility of various multivariate combinations of these biomarkers. We performed a case-controlled validation study in which voided urines from 127 patients (64 tumor bearing subjects) were analyzed. The urinary concentrations of 14 biomarkers (IL-8, MMP-9, MMP-10, SDC1, CCL18, PAI-1, CD44, VEGF, ANG, CA9, A1AT, OPN, PTX3, and APOE) were assessed by enzyme-linked immunosorbent assay (ELISA). Diagnostic performance of each biomarker and multivariate models were compared using receiver operating characteristic curves and the chi-square test. An 8-biomarker model achieved the most accurate BCa diagnosis (sensitivity 92{\%}, specificity 97{\%}), but a combination of 3 of the 8 biomarkers (IL-8, VEGF, and APOE) was also highly accurate (sensitivity 90{\%}, specificity 97{\%}). For comparison, the commercial BTA-Trak ELISA test achieved a sensitivity of 79{\%} and a specificity of 83{\%}, and voided urine cytology detected only 33{\%} of BCa cases in the same cohort. These datashow that a multivariate urine-based assay can markedly improve the accuracy of non-invasive BCa detection. Further validation studies are under way to investigate the clinical utility of this panel of biomarkers for BCa diagnosis and disease monitoring.",
author = "Steven Goodison and Myron Chang and Yunfeng Dai and Virginia Urquidi and Rosser, {Charles J.}",
year = "2012",
month = "10",
day = "19",
doi = "10.1371/journal.pone.0047469",
language = "English (US)",
volume = "7",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "10",

}

TY - JOUR

T1 - A Multi-Analyte Assay for the Non-Invasive Detection of Bladder Cancer

AU - Goodison, Steven

AU - Chang, Myron

AU - Dai, Yunfeng

AU - Urquidi, Virginia

AU - Rosser, Charles J.

PY - 2012/10/19

Y1 - 2012/10/19

N2 - Accurate urinary assays for bladder cancer (BCa) detection would benefit both patients and healthcare systems. Through genomic and proteomic profiling of urine components, we have previously identified a panel of biomarkers that can outperform current urine-based biomarkers for the non-invasive detection of BCa. Herein, we report the diagnostic utility of various multivariate combinations of these biomarkers. We performed a case-controlled validation study in which voided urines from 127 patients (64 tumor bearing subjects) were analyzed. The urinary concentrations of 14 biomarkers (IL-8, MMP-9, MMP-10, SDC1, CCL18, PAI-1, CD44, VEGF, ANG, CA9, A1AT, OPN, PTX3, and APOE) were assessed by enzyme-linked immunosorbent assay (ELISA). Diagnostic performance of each biomarker and multivariate models were compared using receiver operating characteristic curves and the chi-square test. An 8-biomarker model achieved the most accurate BCa diagnosis (sensitivity 92%, specificity 97%), but a combination of 3 of the 8 biomarkers (IL-8, VEGF, and APOE) was also highly accurate (sensitivity 90%, specificity 97%). For comparison, the commercial BTA-Trak ELISA test achieved a sensitivity of 79% and a specificity of 83%, and voided urine cytology detected only 33% of BCa cases in the same cohort. These datashow that a multivariate urine-based assay can markedly improve the accuracy of non-invasive BCa detection. Further validation studies are under way to investigate the clinical utility of this panel of biomarkers for BCa diagnosis and disease monitoring.

AB - Accurate urinary assays for bladder cancer (BCa) detection would benefit both patients and healthcare systems. Through genomic and proteomic profiling of urine components, we have previously identified a panel of biomarkers that can outperform current urine-based biomarkers for the non-invasive detection of BCa. Herein, we report the diagnostic utility of various multivariate combinations of these biomarkers. We performed a case-controlled validation study in which voided urines from 127 patients (64 tumor bearing subjects) were analyzed. The urinary concentrations of 14 biomarkers (IL-8, MMP-9, MMP-10, SDC1, CCL18, PAI-1, CD44, VEGF, ANG, CA9, A1AT, OPN, PTX3, and APOE) were assessed by enzyme-linked immunosorbent assay (ELISA). Diagnostic performance of each biomarker and multivariate models were compared using receiver operating characteristic curves and the chi-square test. An 8-biomarker model achieved the most accurate BCa diagnosis (sensitivity 92%, specificity 97%), but a combination of 3 of the 8 biomarkers (IL-8, VEGF, and APOE) was also highly accurate (sensitivity 90%, specificity 97%). For comparison, the commercial BTA-Trak ELISA test achieved a sensitivity of 79% and a specificity of 83%, and voided urine cytology detected only 33% of BCa cases in the same cohort. These datashow that a multivariate urine-based assay can markedly improve the accuracy of non-invasive BCa detection. Further validation studies are under way to investigate the clinical utility of this panel of biomarkers for BCa diagnosis and disease monitoring.

UR - http://www.scopus.com/inward/record.url?scp=84867663598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867663598&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0047469

DO - 10.1371/journal.pone.0047469

M3 - Article

VL - 7

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 10

M1 - e47469

ER -